Biotech

All Articles

iTeos- GSK's TIGIT superstar shows relevant enhancement

.After revealing a stage 3 launch based upon good midstage results, iTeos and also GSK are ultimatel...

More collaborative FDA can speed up uncommon disease R&ampD: report

.The FDA must be actually more open and collaborative to let loose a surge in commendations of uncom...

Zenas, MBX, Bicara head to Nasdaq in very hot day for biotech IPOs

.It is actually an extraordinarily occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and B...

Atea's COVID antiviral stops working to stop hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has actually neglected another COVID-19 trial, however the biotech ...

Neurocrine's bid to spare mental illness possibility fails

.Neurocrine Biosciences' schizophrenia program pivot has fallen short. The biotech was incapable to ...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has actually made a late entrance to the radioligand celebration, paying one hundred thousan...

F 2G increases $100M for 2nd effort to obtain brand new antifungal to market

.After F2G's 1st try to acquire a new training class of antifungal to market was actually hindered b...

Moderna targets $1.1 B in R&ampD costs cuts, falls 5 systems among productivity stress

.Moderna has pledged to reduce R&ampD costs through $1.1 billion by 2027. The decision to retract th...

Sanofi's $80M bank on Fulcrum dystrophy medicine finishes in period 3 go belly up

.Only 4 months after Sanofi bet $80 thousand in upfront cash on Pivot Therapeutics' losmapimod, the ...

Oncternal equity sinks 60% surrounded by cutbacks, trial terminations

.Cancer provider Oncternal Therapies is actually folding all its clinical tests and also laying off ...